GET DAILY SIGNALSWhy Is Jasper Therapeutics (JSPR) Stock Down -8.19% Today?
Key Takeaways
- JSPR shares fell 8.19% to $15.03, down $1.34 from the prior session's close of $16.37.
- The decline was driven primarily by post-reverse-split volatility and profit-taking following last week's sharp surge.
- Secondary factors include thin trading liquidity and elevated beta, which tend to amplify daily swings in micro-cap biotech names.
- The move follows the company's recently completed warrant tender offer and a 1-for-30 reverse stock split effective November 6, 2026.
- Traders are watching upcoming third-quarter earnings and pipeline catalysts for the next directional signal.
- For deeper detail on valuation and analyst outlook, explore Price Targets, Earnings, and Forecast pages.
- Discover actionable trading ideas and AI-driven strategies on the Trending AI Robots page.
Opening Summary
Jasper Therapeutics, Inc. (JSPR), a clinical-stage biotechnology company based in Redwood City, California, developing therapies for immune-mediated diseases, saw its stock decline 8.19% on Tuesday. Shares traded at $15.03, down $1.34 from the prior session's closing price of $16.37. The drop reflects a pullback in a thinly traded, high-volatility micro-cap following a sharp post-split rally, rather than any single negative corporate announcement.
Post-Reverse-Split Volatility and Profit-Taking
The most significant driver behind the move is turbulence tied to the company's recent 1-for-30 reverse stock split, which became effective on November 6, 2026. Reverse splits are frequently undertaken by companies to lift a lagging share price and regain exchange listing compliance, and they often usher in a period of heightened volatility as the shareholder base and trading dynamics adjust. In the first session following the split, JSPR shares surged roughly 20%, only to give back a portion of those gains in subsequent sessions. Tuesday's decline represents a continuation of that normalization, with traders locking in profits after the initial spike.
Thin Liquidity and Elevated Beta
Jasper Therapeutics trades with relatively low average daily volume for a public company, which means even modest shifts in supply and demand can produce outsized percentage moves. The stock's beta has been estimated above 3.0, indicating it is far more volatile than the broader market. In such conditions, a decline of several percentage points can occur without a discrete news event, as order flow alone moves the price meaningfully.
Capital-Structure and Corporate Actions
The trading environment has also been shaped by recent corporate actions. On November 9, the company announced results of its offer to purchase outstanding warrants, disclosing that approximately 68.94% of eligible warrants were tendered at $0.324 per warrant for an aggregate payment of roughly $2.76 million. While the warrant tender offer is largely a capital-structure cleanup rather than an operational development, the flurry of reverse-split and warrant-related activity has kept the stock in a period of adjustment, contributing to choppy trading.
Market Context and Trading Activity
The decline unfolded against a backdrop of post-split repositioning across the small-cap biotech space. The prior session saw elevated turnover relative to the stock's trailing average, underscoring active repositioning by traders after the split. Technical considerations also play a role: after the November 6 surge established a sharp intraday range, the stock has struggled to hold gains, with support levels being retested as momentum faded. The move appeared idiosyncratic to JSPR rather than a reflection of broad-market selling, as the stock's volatility is driven more by company-specific liquidity dynamics than by index-level sentiment.
What Comes Next for JSPR
Investors will be watching Jasper Therapeutics' upcoming third-quarter earnings report, which is expected in the coming weeks, for updates on cash runway and clinical development progress. The company's pipeline includes vensobafusp alfa (KP104), a dual-complement inhibitor with positive Phase 2 data in paroxysmal nocturnal hemoglobinuria (PNH) and ongoing evaluation in kidney disorders; briquilimab, an anti-KIT antibody; and KP701, a dual-acting monoclonal antibody. Key clinical data readouts and regulatory milestones anticipated over the next year could serve as more durable catalysts. Risks remain, including continued post-split volatility, limited liquidity, and the execution risks inherent to a clinical-stage biotech with no current product revenue.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots from a broader universe of hundreds of bots covering thousands of tickers. Only the strongest performers under current market conditions are featured, and the bots vary by strategy, timeframe, performance metrics, and traded symbols. Investors seeking systematic, data-driven approaches to navigate volatile names may find value in exploring these tools to complement their own research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for JSPR turns negative, indicating new downward trend
JSPR saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 84 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JSPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
JSPR broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JSPR entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for JSPR just turned positive on October 23, 2026. Looking at past instances where JSPR's MACD turned positive, the stock continued to rise in 32 of 37 cases over the following month. The odds of a continued upward trend are 86%.
Following a +6.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where JSPR advanced for three days, in 203 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. JSPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: JSPR's P/B Ratio (397.034) is very high in comparison to the industry average of (3.498). P/E Ratio (-18.129) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JSPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement